

A study on repositioning nalidixic acid *via* lanthanide complexation: Synthesis, characterization, cytotoxicity and DNA/protein binding studies

Ana-Madalina Maciucă¹, Alexandra-Cristina Munteanu^{1*}, Mirela Mihailă², Mihaela Badea³, Rodica Olar³, George Mihai Nitulescu⁴, Cristian V. A. Munteanu⁵, and Valentina Uivarosi^{1*}

¹ Department of General and Inorganic Chemistry, Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, 6 Traian Vuia St, Bucharest 020956, Romania;

² Center of Immunology, Stefan S. Nicolau Institute of Virology, 285 Mihai Bravu Ave, Bucharest 030304, Romania;

³ Department of Inorganic Chemistry, Faculty of Chemistry, University of Bucharest, 90-92 Panduri Str, Bucharest 050663, Romania;

⁴ Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, 6 Traian Vuia Str, Bucharest 020956, Romania;

⁵ Romanian Academy-Institute of Biochemistry (IBAR), 296 Spl. Independenței, 060031 Bucharest, Romania;

* Correspondence: alexandra.ticea@umfcd.ro; valentina.uivarosi@umfcd.ro

Tel.: +4-021-318-0742; Fax: +4-021-318-0750.

Abstract: "Drug repositioning" is a modern strategy used to uncover new applications for out-of-date drugs. In this context, nalidixic acid, the first member of the quinolone class with limited use today, has been selected to obtain nine new metal complexes with lanthanide cations (La^{3+} , Sm^{3+} , Eu^{3+} , Gd^{3+} , Tb^{3+}); the experimental data suggest that the quinolone acts as a bidentate ligand, binding to the metal ion *via* the keto and carboxylate oxygen atoms, findings that are supported by DFT calculations. The cytotoxic activity of the complexes has been studied using tumoral cell lines, MDA-MB-231 and LoVo, and a normal cell line, HUVEC. Their affinity for DNA and the manner of binding have been tested using UV-Vis spectroscopy and competitive binding studies; our results indicate that major and minor groove-binding play a significant role in these interactions. The affinity towards serum proteins has also been evaluated, the complexes displaying higher affinity towards albumin than apo-transferrin.

Keywords: drug repositioning; nalidixic acid; lanthanide ions; anticancer; DNA binding; serum proteins binding.

Table S1. Wavelengths and absorbance (A) values observed in the UV-Vis-NIR spectra of nalidixic acid and complexes.	4
Table S2. IR data (cm ⁻¹) and band assignments for nalidixic acid (Nal), sodium salt of nalidixic acid (Nal-Na ⁺) and M(nal) ₂ compounds, M= La ³⁺ , Sm ³⁺ , Eu ³⁺ , Gd ³⁺ , Tb ³⁺ .	5
Table S3. IR data (cm ⁻¹) and band assignments for nalidixic acid (Nal), sodium salt of nalidixic acid (Nal-Na ⁺) and M(nal) ₃ compounds, M= La ³⁺ , Eu ³⁺ , Gd ³⁺ , Tb ³⁺ .	6
Figure S1. Experimental and predicted vibrational spectra of nalidixic acid and its M(nal) ₂ and M(nal) ₃ metal complexes.	7
Figure S2. Mass spectra for the synthesized complexes: A. La(nal) ₂ ; B. Sm(nal) ₂ ; C. Eu(nal) ₂ ; D. Gd(nal) ₂ ; E. Tb(nal) ₂ ; F. La(nal) ₃ ; G. Eu(nal) ₃ ; H. Gd(nal) ₃ ; I. Tb(nal) ₃ .	14
Figure S3. TG, DTG and DTA curves for the M(nal) ₂ complexes, M= La ³⁺ , Sm ³⁺ , Eu ³⁺ , Gd ³⁺ , Tb ³⁺ .	23
Table S4. Thermal decomposition data (in air flow) for the M(nal) ₂ complexes, M= La ³⁺ , Sm ³⁺ , Eu ³⁺ , Gd ³⁺ , Tb ³⁺ .	24
Figure S4. TG, DTG and DTA curves for the M(nal) ₃ complexes, M= La ³⁺ , Sm ³⁺ , Eu ³⁺ , Gd ³⁺ , Tb ³⁺ .	25
Table S5. Thermal decomposition data (in air flow) for the M(nal) ₃ complexes, M= La ³⁺ , Eu ³⁺ , Gd ³⁺ , Tb ³⁺ .	25
Figure S5. ¹ H-NMR spectrum of nalidixic acid.	26
Figure S6. ¹ H-NMR spectrum of La(nal) ₃ .	26
Table S6. Geometric parameters: bond lengths, bond angles, dihedral angles, charge density, total energy of M(nal) ₂ and M(nal) ₃ .	27
Table S7. IR selected data (experimental vs. predicted) for the optimized structures of Eu(nal) ₂ and Eu(nal) ₃ .	32
Figure S7. Experimental and predicted electronic spectra of nalidixic acid and its metal complexes.	32
Table S8. UV-Vis spectral data for nalidixic acid and complexes (experimental vs. predicted).	35
Figure S8. Cytotoxicity of M(nal) ₂ (M= La ³⁺ , Sm ³⁺ , Eu ³⁺ , Gd ³⁺ , Tb ³⁺) and M(nal) ₃ (M= La ³⁺ , Eu ³⁺ , Gd ³⁺ , Tb ³⁺) complexes tested on the following cell lines: A. HUVEC - 24h, B. HUVEC- 48h, C. LoVo – 24h, D. LoVo-48h, E. MDA-MB 231- 24h and F. MDA-MB 231- 48h.	36
Figure S9. Graphical representations of normalized cell viability vs. log(Concentration). Concentrations were expressed in μM and transformed to the corresponding logarithmic values. Data were normalized against the smallest value of cell viability in this data set, corresponding to cisplatin, and the control corresponding to untreated cells. Results were plotted in GraphPad Prism 8.0.1 using the built-in equation Nonlinear regression (curve fit) – log(inhibitor) vs. normalized response variable slope.	37

Figure S10. Stability assay: UV-vis spectra of the complexes in DMSO-TrisHCl buffer mixture (5 mM Tris-HCl/ 50 mM NaCl, pH 7.4).	40
Table S9. Absorbances of tested compounds in UV-Vis, in DMSO-TrisHCl buffer, [compound]= 20 μ M.	42
Figure S11. Absorption spectra of the tested compounds in the absence and presence of increasing amounts of DNA. [compound] = 20 μ M; [DNA] = 0, 5, 10, 15, 20, 25, 30, 35, 40 μ M. The arrows show the absorption changes upon increasing the DNA concentration.	43
Figure S12. Graphical representations of the DNA-binding constants (K_b) for systems containing [compound] = 20 μ M; [DNA] = 5, 10, 15, 20, 25, 30, 35, 40 μ M. K_b values were calculated using Equation 2 in OriginPro® 2018. Outliers are represented on the graphs as red data points.	45
Figure S13. Fluorescence spectra of the EB - DNA system in the absence and presence of increasing amounts of the tested compounds. λ_{ex} = 500 nm, [EB] = 2 μ M, [DNA] = 10 μ M, [compound] = 0, 5, 10, 15, 20, 25, 30, 35, 40 μ M. Arrows indicate the changes in fluorescence intensities upon increasing the concentrations of the tested compounds.	47
Figure S14. Graphical representations of the K_{SV} constants for systems containing [EB] = 2 μ M, [DNA] = 10 μ M, [compound] = 5, 10, 15, 20, 25, 30, 35, 40 μ M. K_{SV} values were calculated using Equation 3 in OriginPro® 2018. Outliers are represented on the graphs as red data points.	49
Figure S15. Graphical representation of the K_{50} constants for systems containing [EB] = 2 μ M, [DNA] = 10 μ M, [compound] = 5, 10, 15, 20, 25, 30, 35, 40 μ M. K_{50} values were calculated using Equation 3 in OriginPro® 2018. Outliers are represented on the graphs as red data points.	51
Figure S16. Changes in fluorescence intensity of free HSA <i>vs.</i> compound-HSA systems; the black arrows indicate a decrease of the intensity upon the addition of increasing amounts of compound; [HSA] = 2.5 μ M, [compound] = 0, 1, 2, 3, 4, 5, 6, 7, 8 μ M.	53
Figure S17. Changes in fluorescence intensity of free apo-Tf <i>vs.</i> compound-apo-Tf systems; the black arrows indicate a decrease of the intensity upon the addition of increasing amounts of compound. [apo-Tf] = 1 μ M, [compound] = 0, 1, 2, 3, 4, 5, 6, 7, 8 μ M.	55
Figure S18. Variation of the HSA fluorescence peak area upon adding increasing amounts of the studied compounds. [HSA] = 2.5 μ M, [compound] = 0, 1, 2, 3, 4, 5, 6, 7, 8 μ M.	57
Figure S19. Variation of the apo-Tf fluorescence peak area upon adding increasing amounts of the studied compounds. [apo-Tf] = 1 μ M, [compound] = 0, 1, 2, 3, 4, 5, 6, 7, 8 μ M.	59
Figure S20. Classical (left) and modified (right) Stern-Volmer plots for each of the HSA interaction studies.	61
Figure S21. Classical (left) and modified (right) Stern-Volmer plots for the apo-Tf interaction assay	65
Figure S22. Representation of K_a and K_d constants for each of the studied compound-HSA systems.	69
Figure S23. Representation of K_a and K_d constants for each of the studied compound-apo-Tf systems.	73
Figure S24. Synchronous spectra for the HSA interaction systems recorded at $\Delta\lambda$ = 15 nm. [HSA] = 2.5 μ M, [compound] = 0, 1, 2, 3, 4, 5, 6, 7, 8 μ M.	77
Figure S25. Synchronous spectra for the HSA interaction systems recorded at $\Delta\lambda$ = 60 nm. [HSA] = 2.5 μ M, [compound] = 0, 1, 2, 3, 4, 5, 6, 7, 8 μ M.	79
Figure S26. Synchronous spectra of the tested compounds - apo-Tf systems recorded at $\Delta\lambda$ =15 nm. [apo-Tf] = 1 μ M, [compound] = 0, 1, 2, 3, 4, 5, 6, 7, 8 μ M.	80
Figure S27. Synchronous spectra of the tested compounds - apo-Tf interaction systems recorded at $\Delta\lambda$ =60 nm. [apo-Tf] = 1 μ M, [compound] = 0, 1, 2, 3, 4, 5, 6, 7, 8 μ M.	83

Table S1. Wavelengths and absorbance (A) values observed in the UV-Vis-NIR spectra of nalidixic acid and complexes.


Compus	Nalidixic acid									
$\lambda(\text{nm})$	255	-	315	-	-	-	1385	1670	-	-
A	0.757	-	0.829	-	-	-	0.089	0.1846	-	-
La(nal)₂										
$\lambda(\text{nm})$	260	-	335	-	-	-	-	1670	1935	-
A	0.924	-	0.982	-	-	-	-	0.114	0.198	-
Sm(nal)₂										
$\lambda(\text{nm})$	250	-	320	685	1090	1245	1395	1500	1940	-
A	1.009	-	1.054	0.164	0.153	0.181	0.187	0.187	0.260	-
Eu(nal)₂										
$\lambda(\text{nm})$	265	-	340	-	-	-	1455	1675	1935	-
A	0.425	-	0.558	-	-	-	0.132	0.150	0.272	-
Gd(nal)₂										
$\lambda(\text{nm})$	255	-	330	685	-	-	1455	1675	1935	-
A	0.907	-	1.010	0.134	-	-	0.128	0.145	0.247	-
Tb(nal)₂										
$\lambda(\text{nm})$	265	-	345	685	-	-	1455	1680	1940	-
A	0.626	-	0.769	0.275	-	-	0.238	0.253	0.385	-
La(nal)₃										
$\lambda(\text{nm})$	255	-	330	-	-	-	1455	1670	1945	-
A	0.948	-	1.023	-	-	-	0.121	0.135	0.269	-
Eu(nal)₃										
$\lambda(\text{nm})$	260	-	335	-	-	-	1445	1670	1945	-
A	0.304	-	0.460	-	-	-	0.116	0.153	0.275	-
Gd(nal)₃										
$\lambda(\text{nm})$	255	-	325	685	-	-	-	1670	1925	1950
A	0.993	-	1.049	0.279	-	-	-	0.275	0.367	0.363
Tb(nal)₃										
$\lambda(\text{nm})$	245	280	355	685	-	-	1440	1670	1925	1940
A	0.751	0.829	0.922	0.118	-	-	0.106	0.147	0.264	0.261

Table S2. IR data (cm⁻¹) and band assignments for nalidixic acid (Nal) , sodium salt of nalidixic acid (Nal-Na⁺) and M(nal)₂ compounds, M= La³⁺, Sm³⁺, Eu³⁺, Gd³⁺, Tb³⁺.


Nal	Nal-Na ⁺	La(nal) ₂	Sm(nal) ₂	Eu(nal) ₂	Gd(nal) ₂	Tb(nal) ₂	Assignments
-	3376 wb	3725 vw 3399 w	3649 w 3420 wb	3395 wn	3377 wb	3397 wb	v(O-H); COOH, H ₂ O
3044 w	-	3056 w	-	3068 w	-	-	Aromatic v(C-H)
2984 w 2946 w	2923 w	2974 w 2925 w	-	2981 w 2931 w	2981 w 2931 w	2981 w 2932 w	v (CH ₃ - CH ₂)
1707 s	-	-	-	-	-	-	v(C=O); COOH
-	1632 vs	1618	1616	1615	1614	1615	v as (COO ⁻)
1613 s	1606	1570	1568 s	1567 s	1567 s	1568 s	Pyridonic v(C=O)
1561	1535 m	1524	1523 s	1523 s	1523s	1523 s	Pyridonic v (C-N)
1517	1496 m	1499 m	1500m	1499 m	1499 m	1500 m	v (C=C)
1469 s 1442 w	1391 s	1348 m	1347 m	1346 s	1346 s	1347 s	v (-CH); δ (-CH ₃)
-	1438 vs	1443 s	1443 s	1442 s	1441 s	1442 s	v s(COO ⁻)
-	194	175	173	173	173	173	Δ= v as (COO ⁻)- v s (COO ⁻)
1151 w	1130 w	1173 w	1131 m	1130 m	1130 m	1131 m	v (C-N)
1033 w 1006	1035 w	1034 w 1009	1092 w 1050 w	1092 w 1049 w	1092 w 1050 w	1092 w 1050 w	δ (-CH ₂)
803 s 777 w 743w 705 m	771 w 749 s 702 w	758 m	781 w 757 m 704 w	781 w 756 m 703 w	780 w 756 s 704 w	782 w 757 m 704 w	δ (COO ⁻)
656 m 634 m 539 m 504 w 485 m 455 m 424 m	649 m 630 m 560 m 535 m 484 m 446 m 432 m 407 m	656 m 635 w 540 m 502 m 453	657 mw 635 w 541 m 458 m 422 w	657 m 635 w 541 m 469 m	656 m 634 w 539 m 490 m 457 w	658 m 635 w 542 m 492 s 446 w	Ring deformation
		578 m 492 m 477 w 410 s	599 m 559 m 492 s 409 s	559 m 491 s	558 m 408 s	602 w 559 m 469 s 407 s	v (M-O)

Table S3. IR data (cm⁻¹) and band assignments for nalidixic acid (Nal), sodium salt of nalidixic acid (Nal-Na⁺) and M(nal)₃ compounds, M= La³⁺, Eu³⁺, Gd³⁺, Tb³⁺.


Nal	Nal-Na ⁺	La(nal) ₃	Eu(nal) ₃	Gd(nal) ₃	Tb(nal) ₃	Assignments
-	3376 wb	3403 w	3399 wb	3436 wb	3420 wb	v(O-H); COOH, H ₂ O
3044 w	-	3060 w	3061 w	-	3059 w	Aromatic v(C-H)
2984 w 2946 w	2923 w	2972 w	2971 w 2929 w	2968 w	2970 w 2932 w	v (CH ₃ -CH ₂)
1707 s	-	-	-	-	-	v(C=O); COOH
-	1632 vs	1614 s	1615 s	1615 s	1614 s	v as(COO ⁻)
1613 s	1606	1557 s	1558 s	1559 s	1559 s	Pyridonic v(C=O)
1517	1496 m	1499 m	1499 m	1499 m	1499 m	v (C=C)
1469 s	1391 s	1344 m	1345 s	1345 s	1345 s	v (-CH); δ (-CH ₃)
1384 m	1362 m	-	1380 w	1378 w	1378 w	Methyl δ(C-H)
-	1438 vs	1439 s	1441 s	1439 s	1439 s	v s(COO ⁻)
-	194	175	174	176	175	Δ= v as (COO ⁻)- v s(COO ⁻)
1293 m	1298 m	1284 w	1286 m	1284 m	1284 m	δr(-CH ₂)
1151 w	1130 w	1157 w 1129 m	1159 m	1129 m	1128 m	v (C-N)
1033 w 1006 w	1035 w	1049 w	1092 w 1049 w	1102 w 1047 w	1092 w 1049 w	δ (-CH ₂)
803 s 777 w 743 w 705 m	771 w 749 s 702	786 w 754 s 704 w	782 w 757 m 703 w	782 w 758 s 705 w	783 w 758 m 704 w	δ (COO ⁻)
656 m 634 m 539 m 504 m 485 s 455 m 424 w	649 m 630 m 560 m 535 m 484 m 446 m 432 m 407 m	656 m 634 w 541 m 489 s 457 w	657 m 635 w 541 m 488 s 419m	657 m 634 w 542 m 489 m 451 w	657 m 634 w 542 m 488 s 477 s 431 w	Ring deformation
		558 m 425 m	463 w 433 w 402 s	599 m 558 405 s	590 w 558 m 403 s	v (M-O)




FT-IR spectrum of nalidixic acid




Predicted spectrum of nalidixic acid




FT-IR spectrum of nalidixic acid sodium salt (NaI·Na⁺)




FT-IR spectrum of $\text{La}(\text{nal})_2$




Predicted spectrum of $\text{La}(\text{nal})_2$




FT-IR spectrum of $\text{Sm}(\text{nal})_2$




Predicted spectrum of $\text{Sm}(\text{nal})_2$




FT-IR spectrum of $\text{Eu}(\text{nal})_2$




Predicted spectrum of $\text{Eu}(\text{nal})_2$




FT-IR spectrum of Gd(nal)₂




Predicted spectrum of Gd(nal)₂




FT-IR spectrum of Tb(nal)₂






Predicted spectrum of $\text{Tb}(\text{nal})_2$




FT-IR spectrum of $\text{La}(\text{nal})_3$




Predicted spectrum of $\text{La}(\text{nal})_3$






Predicted spectrum of $Gd(nal)_3$




FT-IR spectrum of $Tb(nal)_3$




Predicted spectrum of $Tb(nal)_3$

Figure S1. Experimental and predicted vibrational spectra of nalidixic acid and its $M(nal)_2$ and $M(nal)_3$ metal complexes.


A.




B.




C.




D.







$C_{24}H_{22}GdN_4O_6$
620.078 Da






$C_{26}H_{28}GdN_4O_8S$
698.092 Da





E.






F.



G.



H.



I.




Figure S2. Mass spectra for the synthesized complexes: **A.** La(nal)₂; **B.** Sm(nal)₂; **C.** Eu(nal)₂; **D.** Gd(nal)₂; **E.** Tb(nal)₂; **F.** La(nal)₃; **G.** Eu(nal)₃; **H.** Gd(nal)₃; **I.** Tb(nal)₃.




Figure S3. TG, DTG and DTA curves for the M(nal)₂ complexes, M= La³⁺, Sm³⁺, Eu³⁺, Gd³⁺, Tb³⁺.

Table S4. Thermal decomposition data (in air flow) for the M(nal)₂ complexes, M= La³⁺, Sm³⁺, Eu³⁺, Gd³⁺, Tb³⁺.

Complex	Step	Thermal effect	Temperature range / °C	Δm_{exp} /%	Δm_{calc} /%
[La(nal) ₂ (OH)(H ₂ O)]·2H ₂ O	1	endothermic	55-150	4.3	4.7
	2	exothermic	190-285	23.2	22.9
	3	exothermic	285-340	15.3	15.0
	4	exothermic	340-900	35.9	36.0
	Residue (1/2 La₂O₃)			21.3	21.4
[Sm(nal) ₂ (OH)(H ₂ O)]·3H ₂ O	1	endothermic	50-220	7.7	7.3
	2	exothermic	220-325	24.9	25.2
	3	exothermic	325-950	42.5	42.7
	Residue (1/2 Sm₂O₃)			24.9	24.8
[Eu(nal) ₂ (OH)(H ₂ O)]·3H ₂ O	1	endothermic	55-215	7.4	7.7
	2	exothermic	215-335	25.0	24.8
	3	exothermic	335-900	42.8	42.5
	Residue (1/2 Eu₂O₃)			24.8	25.0
[Gd(nal) ₂ (OH)(H ₂ O)]·3H ₂ O	1	endothermic	50-210	7.5	7.6
	2	exothermic	210-335	24.5	24.7
	3	exothermic	335-950	42.6	42.1
	Residue (1/2 Gd₂O₃)			25.4	25.6
[Tb(nal) ₂ (OH)(H ₂ O)]·1.5H ₂ O	1	endothermic	50-105	3.6	3.9
	2	exothermic	240-340	25.3	25.6
	3	exothermic	340-950	43.6	43.2
	Residue (1/4 Tb₄O₇)			27.5	27.3




Figure S4. TG, DTG and DTA curves for the $\text{M}(\text{nal})_3$ complexes, $\text{M} = \text{La}^{3+}$, Eu^{3+} , Gd^{3+} , Tb^{3+} .

Table S5. Thermal decomposition data (in air flow) for the $\text{M}(\text{nal})_3$ complexes, $\text{M} = \text{La}^{3+}$, Eu^{3+} , Gd^{3+} , Tb^{3+}

Complex	Step	Thermal effect	Temperature range / $^{\circ}\text{C}$	Δm_{exp} /%	Δm_{calc} /%
$[\text{La}(\text{nal})_3(\text{H}_2\text{O})_2] \cdot 6\text{H}_2\text{O}$	1	endothermic	50-175	10.9	11.1
	2	exothermic	175-305	28.3	28.5
	3	exothermic	305-950	44.0	43.7
	Residue (1/2 La_2O_3)			16.8	16.7
$[\text{Eu}(\text{nal})_3(\text{H}_2\text{O})_2] \cdot 2.5\text{H}_2\text{O}$	1	endothermic	50-225	4.7	4.9
	2	exothermic	225-330	28.1	28.2
	3	exothermic	330-960	48.0	47.9
	Residue (1/2 Eu_2O_3)			19.2	19.0
$[\text{Gd}(\text{nal})_3(\text{H}_2\text{O})_2] \cdot 1.5\text{H}_2\text{O}$	1	endothermic	55-220	2.9	2.9
	2	exothermic	220-325	28.6	28.6
	3	exothermic	325-980	48.6	48.7
	Residue (1/2 Gd_2O_3)			19.9	19.8
$[\text{Tb}(\text{nal})_3(\text{H}_2\text{O})_2] \cdot 1.5\text{H}_2\text{O}$	1	endothermic	55-235	3.0	2.9
	2	exothermic	235-335	29.3	29.5
	3	exothermic	335-900	47.7	47.8
	Residue (1/4 Tb_4O_7)			20.0	19.8




Figure S5. ¹H-NMR spectrum of nalidixic acid.











Figure S6. ¹H-NMR spectrum of La(nal)₃.

Table S6. Geometric parameters: bond lengths, bond angles, dihedral angles, charge density, total energy of M(nal)₂ and M(nal)₃.

 <p style="text-align: center;">La(nal)₂</p>	Bond length (Å) La-O1 2.565 La-O2 2.412 La-O21 2.564 La-O22 2.411 La-O41 1.493 La-O43 2.625		Mulliken atomic charge La62 0.679 O1 -0.342 O2 -0.458 O21 -0.354 O22 -0.452 O41 0.112 O43 -0.307 N4 -0.304 N24 -0.301 N50 -0.225 N51 -0.227	
<p>Total energy (a.u.): -1778.62</p>	Bond angle (°) O1-La-O2 62.35 O21-La-O22 62.73 O41-La-O43 92.38 O41-La-O22 117.29 O2-La-O43 86.62 O1-La-O21 66.04 La-O22-C25 152.10 La-O2-C5 153.33		Torsion angle O41-La-O22-C25 126.31 O43-La-O2-C5 -70.32 O43-La-O21-C29 128.66 O41-La-O1-C9 125.93 La-O22-C25-O23 176.10 La-O2-C5-O3 176.66 C8-C14-C28-C34 141.95	
 <p style="text-align: center;">Sm(nal)₂</p>	Bond length (Å) Sm-O1 2.303 Sm-O2 2.299 Sm-O21 2.301 Sm-O22 2.296 Sm-O41 2.320 Sm-O43 2.320		Mulliken atomic charge Sm62 0.871 O1 -0.455 O2 -0.442 O21 -0.458 O22 -0.441 O41 -0.610 O43 -0.245 N4 -0.231 N24 -0.232 N50 -0.226 N51 -0.223	

<p>Total energy (a.u.): -2405.35</p>	<p>Bond angle (°)</p> <p>O1-Sm-O2 84.12</p> <p>O21-Sm-O22 84.42</p> <p>O41-Sm-O43 84.21</p> <p>O41-Sm-O22 95.80</p> <p>O2-Sm-O43 94.11</p> <p>O1-Sm-O21 92.67</p> <p>Sm-O22-C25 120.84</p> <p>Sm-O2-C5 121.80</p>		<p>Torsion angle</p> <p>O41-Sm-O22-C25 -146.83</p> <p>O43-Sm-O2-C5 -151.54</p> <p>O43-Sm-O21-C29 -130.98</p> <p>O41-Sm-O1-C9 -127.69</p> <p>Sm-O22-C25-O23 156.65</p> <p>Sm-O2-C5-O3 158.94</p> <p>C8-C14-C28-C34 106.51</p>	
 <p>Eu(nal)₂</p>	<p>Bond length (Å)</p> <p>Eu-O1 2.432</p> <p>Eu-O2 2.313</p> <p>Eu-O21 2.431</p> <p>Eu-O22 2.310</p> <p>Eu-O41 1.503</p> <p>Eu-O43 2.484</p>		<p>Mulliken atomic charge</p> <p>Eu62 0.973</p> <p>O1 -0.334</p> <p>O2 -0.452</p> <p>O21 -0.351</p> <p>O22 -0.447</p> <p>O41 -0.236</p> <p>O43 -0.297</p> <p>N4 -0.302</p> <p>N24 -0.299</p> <p>N50 -0.226</p> <p>N51 -0.226</p>	
<p>Total energy (a.u.): -2457.44</p>	<p>Bond angle (°)</p> <p>O1-Eu-O2 64.48</p> <p>O21-Eu-O22 65.11</p> <p>O41-Eu-O43 90.62</p> <p>O41-Eu-O22 116.03</p> <p>O2-Eu-O43 87.53</p> <p>O1-Eu-O21 67.02</p> <p>Eu-O22-C25 151.51</p> <p>Eu-O2-C5 152.87</p>		<p>Torsion angle</p> <p>O41-Eu-O22-C25 123.70</p> <p>O43-Eu-O2-C5 -73.01</p> <p>O43-Eu-O21-C29 131.90</p> <p>O41-Eu-O1-C9 122.66</p> <p>Eu-O22-C25-O23 176.70</p> <p>Eu-O2-C5-O3 177.79</p> <p>C8-C14-C28-C34 146.86</p>	

 <p style="text-align: center;">Gd(nal)₂</p>	Bond length (Å) Gd-O1 2.389 Gd-O2 2.309 Gd-O21 2.388 Gd-O22 2.310 Gd-O41 1.511 Gd-O43 2.443		Mulliken atomic charge Gd62 1.016 O1 -0.373 O2 -0.462 O21 -0.374 O22 -0.463 O41 -0.150 O43 -0.317 N4 -0.299 N24 -0.300 N50 -0.226 N51 -0.226	
<p>Total energy (a.u.): -2512.80</p>	Bond angle (°) O1-Gd-O2 63.51 O21-Gd-O22 63.51 O41-Gd-O43 110.04 O41-Gd-O22 118.52 O2-Gd-O43 64.29 O1-Gd-O21 72.96 Gd-O22-C25 154.71 Gd-O2-C5 154.76		Torsion angle O41-Gd-O22-C25 -105.40 O43-Gd-O2-C5 -157.74 O43-Gd-O21-C29 -15.28 O41-Gd-O1-C9 -121.31 Gd-O22-C25-O23 -175.93 Gd-O2-C5-O3 176.26 C8-C14-C28-C34 178.80	
 <p style="text-align: center;">Tb(nal)₂</p>	Bond length (Å) Tb-O1 2.365 Tb-O2 2.294 Tb-O21 2.375 Tb-O22 2.290 Tb-O41 1.509 Tb-O43 2.425		Mulliken atomic charge Tb62 1.001 O1 -0.367 O2 -0.469 O21 -0.370 O22 -0.467 O41 -0.159 O43 -0.311 N4 -0.300 N24 -0.301 N50 -0.225 N51 -0.226	
<p>Total energy (a.u.): -2570.98</p>	Bond angle (°) O1-Tb-O2 64.46 O21-Tb-O22 64.75 O41-Tb-O43 111.05 O41-Tb-O22 124.58 O2-Tb-O43 66.13 O1-Tb-O21 68.52 Tb-O22-C25 153.20 Tb-O2-C5 153.60		Torsion angle O41-Tb-O22-C25 -98.79 O43-Tb-O2-C5 -131.52 O43-Tb-O21-C29 8.75 O41-Tb-O1-C9 -110.54 Tb-O22-C25-O23 -176.44 Tb-O2-C5-O3 173.14 C8-C14-C28-C34 -158.87	

 <p style="text-align: center;">La(nal)₃</p>	Bond length (Å) La1-O74 La1-O81 La1-O80 La1-O83 La1-O77 La1-O78 La1-O76 La1-O79	2.615 2.524 2.487 2.563 2.374 2.557 2.338 2.548	Mulliken atomic charge La1 O74 O81 O80 O83 O77 O78 O76 O79 N84 N85 N86 N87 N88 N89	1.183 -0.304 -0.308 -0.504 -0.362 -0.467 -0.376 -0.470 -0.379 -0.299 -0.228 -0.227 -0.300 -0.298 -0.224
<p>Total energy (a.u.): -2577.37</p>	Bond angle (°) O74-La-O81 O81-La-O80 O80-La-O83 O83-La-O78 O78-La-O77 O77-La-O79 O79-La-O76 O76-La-O74 La-O80-C61 La-O79-C24	101.13 60.36 59.77 63.06 62.95 91.23 62.79 89.32 148.86 140.94	Torsion angle O74-La-O80-C61 O74-La-O83-C51 O74-La-O78-C7 O74-La-O77-C3 O74-La-O79-C24 O74-La-O76-C20 O74-La-O81-H91 La-O76-C20-O19 La-O80-C61-O73 La-O77-C3-O2 N87-C51-C6-C12 N88-C24-N87-C51 N88-C24-N84-C7	111.35 12.16 -179.90 -50.01 113.87 -59.61 -90.16 175.68 -148.64 174.01 2.06 -90.47 -174.19
 <p style="text-align: center;">Eu(nal)₃</p>	Bond length (Å) Eu1-O74 Eu1-O81 Eu1-O80 Eu1-O83 Eu1-O77 Eu1-O78 Eu1-O76 Eu1-O79	2.475 2.474 2.321 2.415 2.285 2.419 2.357 2.418	Mulliken atomic charge Eu1 O74 O81 O80 O83 O77 O78 O76 O79 N84 N85 N86 N87 N88 N89	1.069 -0.287 -0.283 -0.441 -0.347 -0.442 -0.361 -0.438 -0.354 -0.298 -0.225 -0.226 -0.300 -0.301 -0.226










 <p style="text-align: center;">Tb(nal)₃</p>	Bond length (Å)		Mulliken atomic charge	
	Tb1-O74	2.425	Tb1	1.116
	Tb1-O81	2.421	O74	-0.350
	Tb1-O80	2.296	O81	-0.261
	Tb1-O83	2.368	O80	-0.493
	Tb1-O77	2.279	O83	-0.377
	Tb1-O78	2.366	O77	-0.464
	Tb1-O76	2.300	O78	-0.385
	Tb1-O79	2.364	O76	-0.453
			O79	-0.383
			N84	-0.301
			N85	-0.226
			N86	-0.224
			N87	-0.300
			N88	-0.299
			N89	-0.225
<p>Total energy (a.u.): -3369.41</p>	Bond angle (°)		Torsion angle	
	O74-Tb-O81	89.90	O74-Tb-O80-C61	-147.22
	O81-Tb-O80	99.70	O74-Tb-O83-C51	53.72
	O80-Tb-O83	64.04	O74-Tb-O78-C7	164.65
	O83-Tb-O78	86.84	O74-Tb-O77-C3	-108.00
	O78-Tb-O77	65.24	O74-Tb-O79-C24	80.06
	O77-Tb-O79	88.89	O74-Tb-O76-C20	-92.29
	O79-Tb-O76	64.71	O74-Tb-O81-H91	158.09
	O76-Tb-O74	66.91	Tb-O76-C20-O19	178.23
	Tb-O80-C61	153.53	Tb-O80-C61-O73	171.76
	Tb-O79-C24	144.10	Tb-O77-C3-O2	-168.07
			N87-C51-C6-C12	36.88
			N88-C24-N87-C51	-47.12
			N88-C24-N84-C7	-176.51

Table S7. IR selected data (experimental vs. predicted) for the optimized structures of Eu(nal)₂ and Eu(nal)₃.

Assignment	Eu(nal) ₂		Eu(nal) ₃	
	Experimental	Predicted	Experimental	Predicted
v(O-H); COOH, H ₂ O	3395 wb	2871 w 2739 w	3399 wb	2850 w 2815 w 2724 m
v (CH ₃ -CH ₂)	2981 w 2931 w	2780 m 2779 m	2971 w 2921 w	2780 m 2775 m
v as (COO ⁻)	1615 s	1888 s 1871 s	1615 s	1882 s 1862 s
Pyridonic v(C=O)	1567 s	1757 s	1558 s	1768 s 1742 s
Pyridonic v (C-N)	1523 s	1590 m	1523 s	1588 m
v s (COO ⁻)	1442 s	1388 s 1365 w	1441 s	1381 s 1372 s
δ (COO ⁻)	781 w 756 m 703 w	850 w 758 w	782 w 757 m 703 w	759 w 745 w 721 w
Ring deformation	657 m 635 w 541 m 469 m	Numerous peaks of weak intensity in the 800-400 cm ⁻¹ range.	657 m 635 w 541 m	Numerous peaks of weak intensity in the 800-400 cm ⁻¹ range.
v (M-O)	559 m 491 s	633 m 596 w 562 w 276 w	463 m 433 m	627 w 450 w 276 w

w = weak, m = medium, s = sharp, b = broad








Figure S7. Experimental and predicted electronic spectra of nalidixic acid and its metal complexes.

Table S8. UV-Vis spectral data for nalidixic acid and complexes (experimental vs. predicted).

Compound	Band I (nm)		Band II (nm)	
	Experimental	Predicted	Experimental	Predicted
Nalidixic acid	253 (shoulder at 238)	270	335	291
La(nal) ₂	252 (shoulder at 236)	270 253	332	311 (shoulder at 318)
Sm(nal) ₂	253 (shoulder at 238)	302	334	326
Eu(nal) ₂	253 (shoulder at 237)	297 (shoulder at 284) 268 253	333	310
Gd(nal) ₂	251 (shoulder at 236)	292	333	303 351
Tb(nal) ₂	251 (shoulder at 236)	265	332	294
La(nal) ₃	251 (shoulder at 237)	292 270	333	319
Eu(nal) ₃	252 (shoulder at 237)	295 264	334	328
Gd(nal) ₃	252 (shoulder at 237)	294	331	320
Tb(nal) ₃	252 (shoulder at 236)	273	333	297






Figure S8. Cytotoxicity of $M(\text{nal})_2$ ($M = \text{La}^{3+}, \text{Sm}^{3+}, \text{Eu}^{3+}, \text{Gd}^{3+}, \text{Tb}^{3+}$) and $M(\text{nal})_3$ ($M = \text{La}^{3+}, \text{Eu}^{3+}, \text{Gd}^{3+}, \text{Tb}^{3+}$) complexes tested on the following cell lines: **A.** HUVEC – 24h, **B.** HUVEC- 48h, **C.** LoVo – 24h, **D.** LoVo-48h, **E.** MDA-MB 231- 24h and **F.** MDA-MB 231- 48h.

LoVo


$\text{La}(\text{nal})_2$




$\text{Sm}(\text{nal})_2$




$\text{La}(\text{nal})_3$




$\text{Eu}(\text{nal})_3$




$\text{Gd}(\text{nal})_3$



$\text{Tb}(\text{nal})_3$









Figure S9. Graphical representations of normalized cell viability *vs.* log(Concentration). Concentrations were expressed in μM and transformed to the corresponding logarithmic values. Data were normalized against the smallest value of cell viability in this data set, corresponding to cisplatin. Results were plotted in GraphPad Prism 8.0.1 using the built-in equation Nonlinear regression (curve fit) – log(inhibitor) *vs.* normalized response variable slope.







Figure S10. Stability assay: UV-vis spectra of the complexes in DMSO-TrisHCl buffer mixture (5 mM Tris-HCl/ 50 mM NaCl, pH 7.4).

Table S9. Absorbances of tested compounds in UV-Vis, in DMSO-TrisHCl buffer, [compound]= 20 μ M.

t (min)	λ (nm)	0	10	20	30	60	90	120
La(nal)2	251	1.150	1.147	1.147	1.149	1.152	1.155	1.158
	331	0.557	0.557	0.558	0.560	0.561	0.565	0.566
Sm(nal)2	251.5	0.951	0.957	0.959	0.958	0.959	1.100	0.956
	331	0.446	0.453	0.455	0.455	0.456	0.482	0.452
Eu(nal)2	251	0.921	0.920	0.920	0.919	0.954	0.954	0.952
	330.5	0.423	0.425	0.426	0.427	0.444	0.445	0.443
Gd(nal)2	251.5	1.015	1.013	1.014	1.013	1.013	1.015	1.012
	330.5	0.446	0.452	0.454	0.456	0.457	0.459	0.458
Tb(nal)2	251	0.804	0.804	0.805	0.807	0.807	0.809	0.809
	330.5	0.354	0.360	0.362	0.362	0.364	0.366	0.366
La(nal)3	251	1.341	1.338	1.336	1.339	1.358	1.363	1.369
	331.5	0.651	0.657	0.657	0.659	0.671	0.673	0.676
Eu(nal)3	251	1.050	1.049	1.052	1.053	1.055	1.055	1.057
	331	0.479	0.479	0.479	0.479	0.479	0.479	0.479
Gd(nal)3	250.5	1.321	1.318	1.320	1.323	1.325	1.331	1.335
	330.5	0.5974	0.605	0.609	0.612	0.614	0.622	0.623
Tb(nal)3	250.5	1.317	1.314	1.313	1.318	1.321	1.327	1.331
	330.5	0.598	0.605	0.605	0.609	0.610	0.614	0.617








Figure S11. Absorption spectra of the tested compounds in the absence and presence of increasing amounts of DNA. [compound] = 20 μM ; [DNA] = 0, 5, 10, 15, 20, 25, 30, 35, 40 μM . The arrows show the absorption changes upon increasing the DNA concentration.


Nalidixic acid




La(nal)₂




Sm(nal)₂




Eu(nal)₂



Gd(nal)₂



Tb(nal)₂







Figure S12. Graphical representations of the DNA-binding constants (K_b) for systems containing [compound] = 20 μ M; [DNA] = 5, 10, 15, 20, 25, 30, 35, 40 μ M. K_b values were calculated using Equation 2 in OriginPro® 2018. Outliers are represented on the graphs as red data points.












Figure S13. Fluorescence spectra of the EB - DNA system in the absence and presence of increasing amounts of the tested compounds. $\lambda_{\text{ex}} = 500 \text{ nm}$, $[\text{EB}] = 2 \mu\text{M}$, $[\text{DNA}] = 10 \mu\text{M}$, $[\text{compound}] = 0, 5, 10, 15, 20, 25, 30, 35, 40 \mu\text{M}$. Arrows indicate the changes in fluorescence intensities upon increasing the concentrations of the tested compounds.

Nalidixic acid

La(nal)₂Sm(nal)₂Eu(nal)₂Gd(nal)₂Tb(nal)₂






Figure S14. Graphical representations of the K_{SV} constants for systems containing [EB] = 2 μ M, [DNA] = 10 μ M, [compound] = 5, 10, 15, 20, 25, 30, 35, 40 μ M. K_{SV} values were calculated using Equation 3 in OriginPro® 2018. Outliers are represented on the graphs as red data points.


Nalidixic acid




La(nal)₂




Sm(nal)₂




Eu(nal)₂



Gd(nal)₂



Tb(nal)₂












Figure S15. Graphical representation of the K_{50} constants for systems containing [EB] = 2 μM , [DNA] = 10 μM , [compound] = 5, 10, 15, 20, 25, 30, 35, 40 μM . K_{50} values were calculated using Equation 3 in OriginPro® 2018. Outliers are represented on the graphs as red data points.

Nalidixic acid

 $\text{La}(\text{nal})_2$  $\text{Sm}(\text{nal})_2$  $\text{Eu}(\text{nal})_2$  $\text{Gd}(\text{nal})_2$  $\text{Tb}(\text{nal})_2$ 





Figure S16. Changes in fluorescence intensity of free HSA *vs.* compound-HSA systems; the black arrows indicate a decrease of the intensity upon the addition of increasing amounts of compound; [HSA] = 2.5 μM , [compound] = 0, 1, 2, 3, 4, 5, 6, 7, 8 μM .







Figure S17. Changes in fluorescence intensity of free apo Tf *vs.* compound-apo Tf systems; the black arrows indicate a decrease of the intensity upon the addition of increasing amounts of compound. [apo-Tf] = 1 μM , [compound] = 0, 1, 2, 3, 4, 5, 6, 7, 8 μM .







Figure S18. Variation of the HSA fluorescence peak area upon adding increasing amounts of the studied compounds. [HSA] = 2.5 μM, [compound] = 0, 1, 2, 3, 4, 5, 6, 7, 8 μM.








Figure S19. Variation of the apo-Tf fluorescence peak area upon adding increasing amounts of the studied compounds. [apo-Tf] = 1 μM, [compound] = 0, 1, 2, 3, 4, 5, 6, 7, 8 μM.



Classical Stern-Volmer

Modified Stern-Volmer



Nalidixic acid



La(nal)₂





Sm(nal)₂





Classical Stern-Volmer

Modified Stern-Volmer



Eu(nal)₂



Gd(nal)₂









Tb(nal)₂



Classical Stern-Volmer

Modified Stern-Volmer

 La(nal)_3  Eu(nal)_3  Gd(nal)_3 






Figure S20. Classical (left) and modified (right) Stern-Volmer plots for each of the HSA interaction studies.



Classical Stern-Volmer

Modified Stern-Volmer



Nalidixic acid



La(nal)₂









Sm(nal)₂



Classical Stern-Volmer

Modified Stern-Volmer



 $\text{Eu}(\text{nal})_2$  $\text{Gd}(\text{nal})_2$  $\text{Tb}(\text{nal})_2$





La(nal)₃

Classical Stern-Volmer



Modified Stern-Volmer



Eu(nal)₃



Gd(nal)₃



Tb(nal)₃

Classical Stern-Volmer

Modified Stern-Volmer









Figure S21. Classical (left) and modified (right) Stern-Volmer plots for the apo-Tf interaction assay.



Nalidixic acid	
Ka	Kd



La(nal) ₂	
----------------------	--





Sm(nal) ₂	
----------------------	--





Eu(nal)₂

Ka



Kd



Gd(nal)₂





Tb(nal)₂





La(nal)₃

Ka

Kd



Eu(nal)₃



Gd(nal)₃







Figure S22. Representation of Ka and Kd constants for each of the studied compound-HSA systems..






Eu(nal)₂





Gd(nal)₂

Ka



Kd



Tb(nal)₂





La(nal)₃



Eu(nal)₃

Ka

Kd












Figure S23. Representation of Ka and Kd constants for each of the studied compound-apo-Tf systems.

Nalidixic acid

 $\text{La}(\text{nal})_2$  $\text{Sm}(\text{nal})_2$  $\text{Eu}(\text{nal})_2$  $\text{Gd}(\text{nal})_2$  $\text{Tb}(\text{nal})_2$ 





Figure S24. Synchronous spectra for the HSA interaction systems recorded at $\Delta\lambda = 15$ nm. $[\text{HSA}] = 2.5 \mu\text{M}$, $[\text{compound}] = 0, 1, 2, 3, 4, 5, 6, 7, 8 \mu\text{M}$.







Figure S25. Synchronous spectra for the HSA interaction systems recorded at $\Delta\lambda = 60$ nm. $[\text{HSA}] = 2.5 \mu\text{M}$, $[\text{compound}] = 0, 1, 2, 3, 4, 5, 6, 7, 8 \mu\text{M}$.







Figure S26. Synchronous spectra of the tested compounds - apo-Tf systems recorded at $\Delta\lambda=15$ nm. [apo-Tf] = 1 μM , [compound] = 0, 1, 2, 3, 4, 5, 6, 7, 8 μM .






Figure S27. Synchronous spectra of the tested compounds - apo-Tf interaction systems recorded at $\Delta\lambda=60$ nm. [apo-Tf] = 1 μM , [compound] = 0, 1, 2, 3, 4, 5, 6, 7, 8 μM .